Healthcare, Pharma & Life Sciences

Clorox Launches Purell ProCare, Merging CloroxPro and GOJO for B2B

Image
Clorox Launches Purell ProCare, Merging CloroxPro and GOJO for B2B

Oakland, Calif. – September 28, 2026 -- The Clorox Company has officially launched Clorox Purell ProCare, a new business-to-business health and hygiene platform formed by merging CloroxPro with GOJO, the maker of Purell, following Clorox's acquisition of GOJO earlier in 2026.

Clorox Purell ProCare unifies sales and distribution under one network

The new entity operates a unified sales and service organization alongside a network of distributors, giving professional and healthcare customers access to a combined portfolio spanning Clorox, Purell, Pine-Sol and Glad brands. The business is headquartered in Akron, Ohio, with additional offices in Pleasanton, California, and Toronto, Ontario, plus operations in Ashland, Cuyahoga Falls and Wooster, Ohio, and Alpharetta, Georgia.

Study: Fertility Patients Spend $543, 3 Cycles Before Coverage Starts

Image
Study: Fertility Patients Spend $543, 3 Cycles Before Coverage Starts

New York – September 28, 2026 -- Women trying to conceive spend a median of $543 and track three hormone cycles out of pocket before fertility insurance coverage typically begins, according to a real-world analysis released by Oova and Flora Fertility.

Analysis tracks 49 users who conceived using at-home hormone monitoring

The study examined data from 49 Oova users spanning 2021 to 2026 who subsequently reported a pregnancy. Users tracked a median of four hormone cycles overall, with some spending more than $2,000 across multiple years before conceiving.

Median conception journey runs three cycles, with 73% succeeding within six

Among the group, the median time to conception was three tracked cycles, and 73% conceived within six cycles. The average monitoring spend of roughly $543 compares with a published average of $1,000 for a fertility diagnostic workup and $38,000 for a single IVF cycle.

MOYOM Biotech Lands Cathay Capital Funding for Global Expansion

Image
MOYOM Biotech Lands Cathay Capital Funding for Global Expansion

Shanghai – – September 28, 2026 -- MOYOM Biotech, a Chinese developer of regenerative aesthetic biomaterials, has secured a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital, to fund international expansion of its flagship CaHA-based implant brand Aphranel®.

Cathay Capital Fund Backed by L'Oréal Targets Beauty and Skin Science Innovation

The investment vehicle was jointly established by Cathay Capital, L'Oréal and the Shanghai Jing'an District Government. Cathay Capital's broader portfolio includes Moonshot AI (Kimi), autonomous driving firm Momenta, U.S. fintech Chime, digital asset platform Ledger, delivery platform Glovo and AI biotech company Owkin.

IDEAYA Biosciences Promotes Michael White to President, R&D

Image
IDEAYA Biosciences Promotes Michael White to President, R&D

South San Francisco, Calif. – September 28, 2026 -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA) promoted Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.

White expands authority over IDEAYA's oncology pipeline after five years as CSO

Dr. White has served as Chief Scientific Officer at IDEAYA since 2021, overseeing research into synthetic lethality and antibody-drug conjugate (ADC) programs targeting solid tumors. The precision medicine oncology company's pipeline spans multiple indications, including uveal melanoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, colorectal cancer and breast cancer.

AxisCare Launches AI Receptionist to Cut Home Care Call-Off Chaos

Image
AxisCare Launches AI Receptionist to Cut Home Care Call-Off Chaos

Waco, Texas – – September 28, 2026 -- AxisCare has launched Axi Assist, an AI-powered receptionist built into its home care management platform to handle caregiver call-offs and missed clock-ins around the clock, including nights, weekends, and holidays.

Axi Assist captures caregiver call-off details and triggers scheduling workflows immediately, even outside office hours.

The tool answers calls, records information, and starts rescheduling processes without waiting for a coordinator to check voicemail, addressing a recurring operational bottleneck for home care agencies that rely on on-call staff to cover gaps.

SOLA Japan Wins ¥6B AMED Grant for ALS Gene Therapy SOL-257

Tokyo – September 28, 2026 -- SOLA Biosciences Japan GK has secured a grant of approximately 6 billion yen over five years from Japan's Agency for Medical Research and Development (AMED) to advance SOL-257, a gene therapy candidate targeting the TDP-43 protein implicated in amyotrophic lateral sclerosis (ALS). The award, granted under AMED's Strengthening Program for Pharmaceutical Startup Ecosystem, was announced June 5, 2026, and positions SOLA Japan as the company's central development hub for the program.

AMED grant targets a pathology present in 97% of ALS cases

SOL-257 is designed to restore the structure and function of misfolded TDP-43, a protein that becomes mislocalized and aggregated in motor neurons in roughly 97% of ALS cases, according to SOLA. The company describes SOL-257 as a potentially first-in-class, disease-modifying gene therapy built on its proprietary JUMP70 platform.

Grünenthal, DKSH Expand Pain Drug Access to Eight Asia-Pacific Markets

Image
Grünenthal, DKSH Expand Pain Drug Access to Eight Asia-Pacific Markets

Aachen, Germany – September 28, 2026 -- Grünenthal and DKSH Business Unit Healthcare have signed a new commercialisation agreement to bring four pain medicines, Qutenza, Vimovo, Palexia and Zomig, to eight Asia-Pacific markets: Hong Kong, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam.

DKSH takes over local regulatory filings and distribution across eight markets

Under the agreement, DKSH will seek local marketing authorisations and handle marketing, medical affairs, market access, sales and distribution for the four medicines in each of the eight markets, pending regulatory approval. Grünenthal will retain manufacturing responsibility through its global production network. Each market could gain access to up to four new medicines depending on approval timelines.

Akeso Enrolls First Patient in Global Phase III Gastric Cancer Trial

Hong Kong – September 28, 2026 -- Akeso, Inc. (9926.HK) has enrolled the first patient in COMPASSION-37, a global Phase III head-to-head trial testing its bispecific antibody cadonilimab against nivolumab as first-line treatment for HER2-negative advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinoma.

Trial pits cadonilimab plus chemotherapy against nivolumab-based standard of care

The multicenter study compares cadonilimab combined with chemotherapy to chemotherapy with or without nivolumab in previously untreated, unresectable or metastatic G/GEJ patients. It is co-led by Dr. Yelena Y. Janjigian of Memorial Sloan Kettering Cancer Center, Professor Markus Möhler of Johannes Gutenberg University Mainz, and Professors Jiafu Ji and Lin Shen of Peking University Cancer Hospital. Janjigian, Möhler and Shen were investigators on the earlier CheckMate 649 trial, which established nivolumab plus chemotherapy as a global first-line standard.

Cuvo Health Report: Only 14 States Ease Telehealth Licensing

Image
Cuvo Health Report: Only 14 States Ease Telehealth Licensing

Wilmington, Del. – September 28, 2026 -- A new 51-jurisdiction dataset from Cuvo Health shows that only 14 states offer out-of-state physicians a telehealth registration or telemedicine license short of full licensure, exposing a costly compliance gap for digital health startups seeking national scale.

Accuray, Samsung NeuroLogica Partner on CyberKnife Volumetric Imaging

Image
Accuray, Samsung NeuroLogica Partner on CyberKnife Volumetric Imaging

Madison, Wis. – September 27, 2026 -- Accuray Incorporated (NASDAQ: ARAY) has signed agreements with Samsung HME America's NeuroLogica Corp. unit to pursue advanced volumetric imaging capabilities for its CyberKnife System, the companies announced at the ASTRO Annual Meeting in Boston.

Samsung's mobile CT expertise meets Accuray's robotic radiosurgery platform

The collaboration pairs Samsung NeuroLogica's mobile computed tomography and volumetric imaging technology with Accuray's precision treatment delivery, robotic radiosurgery and motion-management systems. No commercial product has been announced; the partnership will proceed through phased technical, clinical and commercial evaluation subject to regulatory requirements.